NASDAQ:AMRN - Amarin Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.25 +0.04 (+1.25 %)
(As of 06/21/2018 07:52 AM ET)
Previous Close$3.21
Today's Range$3.20 - $3.27
52-Week Range$2.66 - $4.60
Volume1.10 million shs
Average Volume1.50 million shs
Market Capitalization$938.34 million
P/E Ratio-13.00
Dividend YieldN/A
Amarin logoAmarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has collaboration with Mochida Pharmaceutical Co., Ltd. for the development of EPA-Based drug products and indications. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.

Receive AMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity Ratio-2.30
Current Ratio1.74
Quick Ratio1.45


Trailing P/E Ratio-13.00
Forward P/E Ratio-8.78
P/E GrowthN/A

Sales & Book Value

Annual Sales$181.10 million
Price / Sales5.25
Cash FlowN/A
Price / CashN/A
Book Value($0.33) per share
Price / Book-9.85


EPS (Most Recent Fiscal Year)($0.25)
Net Income$-67,860,000.00
Net Margins-37.30%
Return on EquityN/A
Return on Assets-39.78%


Outstanding Shares292,320,000

Amarin (NASDAQ:AMRN) Frequently Asked Questions

What is Amarin's stock symbol?

Amarin trades on the NASDAQ under the ticker symbol "AMRN."

How were Amarin's earnings last quarter?

Amarin Co. plc (NASDAQ:AMRN) released its quarterly earnings results on Wednesday, May, 2nd. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.08). The biopharmaceutical company had revenue of $43.80 million for the quarter, compared to analyst estimates of $43.75 million. The firm's revenue was up 26.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.08) EPS. View Amarin's Earnings History.

When is Amarin's next earnings date?

Amarin is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Amarin.

What price target have analysts set for AMRN?

3 Wall Street analysts have issued twelve-month price targets for Amarin's stock. Their forecasts range from $7.00 to $10.00. On average, they anticipate Amarin's stock price to reach $9.00 in the next twelve months. View Analyst Ratings for Amarin.

What are Wall Street analysts saying about Amarin stock?

Here are some recent quotes from research analysts about Amarin stock:
  • 1. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (5/7/2018)
  • 2. Cantor Fitzgerald analysts commented, "Amarin announced the presentation of two posters at the National Kidney Foundation 2018 Spring Clinical Meetings in Austin, TX. These data, along with what we expect to be positive results from Amarin’s REDUCE-IT study by 3Q18, support our investment thesis for the stock. This is because a large portion of the male and female patients enrolled in this outcomes study are anticipated to also be diagnosed with type 2 diabetes." (4/12/2018)

Who are some of Amarin's key competitors?

Who are Amarin's key executives?

Amarin's management team includes the folowing people:
  • Mr. John F. Thero, Chief Exec. Officer, Pres and Director (Age 57)
  • Mr. Michael W. Kalb CPA, Chief Financial Officer and Sr. VP (Age 47)
  • Dr. Steven B. Ketchum, Chief Scientific Officer, Pres of R&D and Sr. VP (Age 53)
  • Mr. Joseph T. Kennedy J.D., Chief Compliance Officer, Exec. VP of Strategic Initiatives, Gen. Counsel and Sec. (Age 50)
  • Mr. Rami Daoud, Sr. VP of Corp. Devel.

Has Amarin been receiving favorable news coverage?

News articles about AMRN stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amarin earned a media sentiment score of 0.13 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.37 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Amarin's major shareholders?

Amarin's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Farallon Capital Management LLC (1.56%), Rock Springs Capital Management LP (1.37%), BlackRock Inc. (1.14%), Sofinnova Ventures Inc (1.14%), Alkeon Capital Management LLC (0.67%) and Opaleye Management Inc. (0.60%). Company insiders that own Amarin stock include John F Thero, Joseph T Kennedy and Steven B Ketchum. View Institutional Ownership Trends for Amarin.

Which institutional investors are selling Amarin stock?

AMRN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., GSA Capital Partners LLP and California Public Employees Retirement System. Company insiders that have sold Amarin company stock in the last year include Joseph T Kennedy and Steven B Ketchum. View Insider Buying and Selling for Amarin.

Which institutional investors are buying Amarin stock?

AMRN stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Sofinnova Ventures Inc, Alkeon Capital Management LLC, Opaleye Management Inc., Eversept Partners LLC, A.R.T. Advisors LLC, DekaBank Deutsche Girozentrale and Claraphi Advisory Network LLC. View Insider Buying and Selling for Amarin.

How do I buy shares of Amarin?

Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amarin's stock price today?

One share of AMRN stock can currently be purchased for approximately $3.25.

How big of a company is Amarin?

Amarin has a market capitalization of $938.34 million and generates $181.10 million in revenue each year. The biopharmaceutical company earns $-67,860,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Amarin employs 241 workers across the globe.

How can I contact Amarin?

Amarin's mailing address is 2 Pembroke House Upper Pembroke Street 28-32, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected]

MarketBeat Community Rating for Amarin (AMRN)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  471 (Vote Outperform)
Underperform Votes:  280 (Vote Underperform)
Total Votes:  751
MarketBeat's community ratings are surveys of what our community members think about Amarin and other stocks. Vote "Outperform" if you believe AMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.